Tresor Surgical Spirit

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines in cases of methanol poisoning in pediatric patients.

Adults: In cases of methanol poisoning, immediate medical attention is required. Treatment typically involves the administration of fomepizole or ethanol as antidotes, along with supportive care and correction of metabolic acidosis. Dosing should be guided by clinical protocols.

Mechanism of action

Methanol is metabolized in the liver by alcohol dehydrogenase to formaldehyde, which is further oxidized to formic acid. Formic acid is responsible for many of the toxic effects of methanol, including metabolic acidosis and visual impairment. The severity of toxicity can depend on individual susceptibility and the activity of metabolic pathways, particularly those involving folic acid metabolism, which is necessary for formate metabolism.

Pharmacodynamics

Methanol toxicity manifests through its metabolic products, primarily formic acid, which decreases blood pH, leading to metabolic acidosis. This acidosis can cause complications such as respiratory distress and cardiovascular instability. The accumulation of formic acid also impacts mitochondrial function and can lead to cellular hypoxia and damage, particularly in the optic nerve, resulting in visual impairment or blindness.

Pharmacokinetics

Methanol is rapidly absorbed through the gastrointestinal tract and can cross the blood-brain barrier. It is metabolized primarily in the liver, with a significant portion converted to formaldehyde and then to formic acid. The elimination half-life of methanol varies and can be prolonged in cases of intoxication due to saturation of metabolic pathways. The time to peak concentrations can vary significantly; toxicity can develop long after initial ingestion, complicating management.

Adverse effects

• Metabolic acidosis
• Visual impairment
• Headaches
• Nausea
• Vomiting
• Dizziness
• Coma
• Death

Precautions

• Use with caution in individuals with liver impairment
• Monitor for signs of toxicity, especially in cases of suspected overdose

Pregnancy

Methanol is classified as a teratogen and should be avoided during pregnancy due to the risk of fetal toxicity and developmental harm.

Breast-feeding

Methanol is not recommended while breastfeeding due to potential harmful effects in the nursing infant.

Storage

Store in a cool, dry place away from light and heat. Keep container tightly closed and out of reach of children.

Dosage

Children: Refer to specific drug formulation guidelines as methylated compounds encompass a wide range of pharmacological agents, each with its own dosing recommendations.

Adults: Refer to specific drug formulation guidelines as methylated compounds encompass a wide range of pharmacological agents, each with its own dosing recommendations.

Mechanism of action

Methylation can affect the pharmacokinetics of drugs by influencing their solubility, absorption, distribution, metabolism, and excretion. Methylated drugs may have enhanced or reduced activity compared to their unmethylated counterparts, depending on the target receptors and pathways involved. In the context of neurotransmitter metabolism, for example, methylation can lead to the production of active metabolites that exert their effects on the central nervous system.

Pharmacodynamics

The pharmacodynamics of methylated compounds can vary widely depending on the specific drug and its receptor interactions. Methylation can enhance lipophilicity, allowing for better penetration through biological membranes, which may increase the drug's potency or duration of action. Additionally, methylation can affect the binding affinity of a drug to its target, influencing the therapeutic outcome.

Pharmacokinetics

The pharmacokinetics of methylated compounds is influenced by their chemical structure, which affects their absorption, distribution, metabolism, and excretion. Methylated drugs may exhibit altered half-lives due to changes in metabolic pathways. For example, methylation can either activate or deactivate a drug, depending on the metabolic enzymes involved. The presence of methyl groups can also impact the drug's stability and solubility in biological fluids.

Pregnancy

The safety of methylated compounds during pregnancy varies depending on the specific compound and its pharmacological properties. It is essential to assess the benefits and risks before prescribing.

Breast-feeding

Methylated compounds may be excreted in breast milk; caution is advised when administering these medications to breastfeeding mothers.

Storage

Store in a cool, dry place away from light. Specific storage conditions can vary based on the specific methylated compound.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Antiseptic use
• Solvent in pharmaceutical preparations
• Management of alcohol withdrawal syndrome
• Treatment of methanol poisoning (as an antidote)

Dosage

Children: Refer to specific medical guidelines or formularies for dosing information, as it varies widely based on the indication and formulation used.

Adults: Refer to specific medical guidelines or formularies for dosing information, as it varies widely based on the indication and formulation used.

Mechanism of action

Ethanol acts primarily by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased inhibitory neurotransmission. It also inhibits the N-methyl-D-aspartate (NMDA) receptor, which contributes to its depressant effects. Additionally, ethanol affects the release of various neurotransmitters, including dopamine, which plays a role in the reward pathway and contributes to its addictive properties.

Pharmacodynamics

Ethanol's pharmacodynamic effects are dose-dependent. Low doses can produce mild euphoria, relaxation, and impaired motor coordination. As the dose increases, effects can progress to sedation, respiratory depression, and potentially coma or death in cases of severe intoxication. Chronic use can lead to tolerance and dependence, with withdrawal symptoms occurring upon cessation.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, with peak blood concentrations occurring within 30 to 90 minutes after ingestion. It is distributed throughout body water, with a volume of distribution of approximately 0.5 to 0.7 L/kg. Ethanol is metabolized primarily by the liver through the action of alcohol dehydrogenase and aldehyde dehydrogenase, with a typical elimination rate of 10 to 20 mg/dL per hour. It is excreted in urine, breath, and sweat.

Adverse effects

• Nausea
• Vomiting
• Dizziness
• Headache
• Irritation of mucous membranes
• Depression of the central nervous system

Interactions

• Increased sedation with other CNS depressants
• Potential enhancement of effects of certain medications metabolized by the liver

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor for signs of excessive sedation or respiratory depression
• Avoid use in patients with known hypersensitivity to alcohol or other ingredients

Pregnancy

Alcohol is generally advised against during pregnancy due to risks of fetal alcohol spectrum disorders and other complications.

Breast-feeding

Alcohol can pass into breast milk, and breastfeeding mothers should limit intake to avoid potential effects on the infant.

Storage

Store in a cool, dry place away from light and out of reach of children. Keep tightly closed.

Formulations

• Spirit (ethanol-based liquid)
• Spirit of ammonia
• Spirit of camphor
• Spirit of turpentine

Mechanism of action

... The metabolic mechanisms of methanol toxicity /are/ reviewed. ... It is noted that the most severe toxicity occurs many hours following peak blood and tissue methanol concentrations so that these do not necessarily provide an accurate indication of toxicity. Individual differences are seen both in this latent period and in individual susceptibility to methanol. This susceptibility may depend on the activity of folic acid requiring metabolic reactions involved in formate metabolism, formate being an intermediate produced during methanol oxidation and responsible for many toxic effects of methanol. Studies of the characteristics of methanol poisoning in non-primates and monkeys are examined. Despite the ingestion of lethal doses of methanol, non-primates generally do not develop significant metabolic acidosis nor impairment of vision, and no consistent histopathology has been demonstrated in these species. In monkeys, results suggest that the latent period represents a period of compensated metabolic acidosis; when compensatory mechanisms are exhausted, blood pH begins to drop. Formate accumulates and produces acidosis in the methanol poisoned monkey, but not in the rat, apparently due to a slower rate of formate metabolism to carbon dioxide in the monkey. ... Studies demonstrating the role of alcohol dehydrogenase in methanol metabolism in the monkey are reported; however, the catalase/peroxidative system which participates in methanol metabolism in rats apparently does not function in the monkey. Formaldehyde and formate metabolism are also examined. The regulation of the rate of formate metabolism is governed by regulation of the hepatic tetrahydrofolate concentrations. ... Further research is needed to determine what step or process it is which places the primate at a distinct liability in the metabolic disposition of one carbon moieties. Methanol toxicity is observed in monkeys and humans but is not seen in rats or mice. The expression of methanol poisoning is related to the ability of an animal to metabolize formate to carbon dioxide. Since the rate of formate oxidation is related to hepatic tetrahydrofolate content and the activites of folate dependent enzymes, studies were designed to determine hepatic concentrations of hepatic tetrahydrofolate and activites of folate dependent enzymes of human liver and livers of species considered insensitive to methanol poisoning. An excellent correlation between hepatic tetrahydrofolate and maximal rates of formate oxidation has been observed. In human liver, levels were only 50% of those observed for rat liver and similar to those found in monkey liver. Total folate was also lower (60% decreased) in human liver than that found in rat or monkey liver. Interestingly, mouse liver contains much higher hepatic tetrahydrofolate and total folate than rat or monkey liver. This is consistent with higher formate oxidation rates in this species. A second important observation has been made. 10-Formyltetrahydrofolate dehydrogenase activity, the enzyme catalyzing the final step of formate oxidation to carbon dioxide, was markedly reduced in both monkey and human liver. Thus, two mechanisms may be operative in explaining low formate oxidation in species susceptible to methanol toxicity, low hepatic tetahydrofolate levels and reduced hepatic 10-formyltetrahydrofolate dehydrogenase activity. Formic acid, the toxic metabolite of methanol, has been hypothesized to produce retinal and optic nerve toxicity by disrupting mitochondrial energy production. It has been shown in vitro to inhibit the activity of cytochrome oxidase, a vital component of the mitochondrial electron transport chain involved in ATP synthesis. Inhibition occurs subsequent to the binding of formic acid to the ferric heme iron of cytochrome oxidase, and the apparent inhibition constant is between 5 and 30 mM. Concentrations of formate present in the blood and tissues of methanol-intoxicated humans, non-human primates and rodent m